European Data Support Benefit of Capecitabine/Irinotecan Regimen in Advanced Colorectal Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

ORLANDO-Combination therapy with irinotecan (CPT-11, Camptosar) and capecitabine (Xeloda) has the potential to become a mainstay of treatment for colorectal cancer, according to David J. Kerr, MD, Rhodes Professor of Therapeutics and Clinical Pharmacology and director of the National Translational Cancer Research Network, Oxford University

ORLANDO—Combination therapy with irinotecan (CPT-11, Camptosar) and capecitabine (Xeloda) has the potential to become a mainstay of treatment for colorectal cancer, according to David J. Kerr, MD, Rhodes Professor of Therapeutics and Clinical Pharmacology and director of the National Translational Cancer Research Network, Oxford University.

Both drugs are active as single agents, show minimal overlap in toxicities, and have been highly active in xenograft models.

Speaking at an industry-sponsored symposium held in conjunction with the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO), Dr. Kerr discussed European phase I/II clinical trials of the combination and future phase III investigations.

Dr. Kerr is the lead investigator in an irinotecan/capecitabine study conducted in the United Kingdom and The Netherlands.

"The patients in the UK/Netherlands study may have received fluorouracil (5-FU)/leucovorin in an adjuvant setting, but they were chemotherapy naïve in terms of treatment for their advanced disease," Dr. Kerr said. "We saw responses at every dose level. Looking at the totality, there was a 52% overall response rate. So the combination maintained a very decent response rate, and we saw it all the way across."

Dose-limiting toxicities were diarrhea and neutropenia. The investigators chose a dosage level of 250 mg/m² bid of irinotecan and 1,000 mg/m² bid of capecitabine on days 1 to 14 for their upcoming phase III trial. At this dosage level, hand-foot syndrome was not a problem.

Confirmatory Studies

A multicenter French trial by J.P. Delord et al (abstract 397) confirmed the results of the UK/Netherlands study in a group of patients with a wide range of gastrointestinal tumors. Many of the 23 patients had been treated with first- and second-line chemotherapy, Dr. Kerr said, and represented a more conventionally refractory phase I trial grouping.

The French investigators defined the same recommended dose schedule of 250 mg/m² of irinotecan and 1,000 mg/m² bid of capecitabine, Dr. Kerr said.

Dose-limiting toxicities, as expected, were diarrhea and neutropenia.

"It is always very comforting in phase I when you see a convergence of efforts from different trial groups in defining the same regimen," he noted. "In terms of preliminary treatment results, again this was a very different patient population from ours, with multiple previous cycles for advanced disease. But even here, you had some responses and stable disease."

Italian Study

An Italian phase II trial of irinotecan and capecitabine compared irinotecan (300 mg/m² on day 1) and capecitabine (1,250 mg/m² bid on days 2 to 15) with a split dose of irinotecan (150 mg/m² on days 1 and 8) and capecitabine (1,250 mg/m² bid on days 2 to 15).

The investigators had to lower these doses because of unacceptable levels of grade 3-4 toxicities. The lower
doses were 240 mg/m² of irinotecan and 1,000 mg/m² bid of capecitabine, similar again to those defined in the UK/Netherlands trial.

Gastrointestinal toxicity was the most common side effect but was reduced with the lowered dosages. Dr. Kerr noted, however, that there was one treatment-related death due to dehydration from diarrhea and that the fractionated irinotecan dose appeared to be more toxic.

Total response rates were well maintained at around 50% for both arms of the trial—51% for arm 1 (full-dose irinotecan) and 45% for arm 2 (fractionated-dose irinotecan). These results again were similar to those of the UK/Netherlands trial.

"You get the feeling that there is quite a large emerging database pointing us toward what we feel is the right regimen," Dr. Kerr said. "Grade 3-4 toxicity rates are running about 10% to 15%, and response rates are running about 50%."

Upcoming Trials

Upcoming trials include a phase III trial (EORTC 40015) that will randomize close to 700 patients to the irinotecan/capecitabine regimen of the UK/Netherlands trial or the European gold-standard of biweekly infused 5-FU/leucovorin plus irinotecan at 180 mg/m² on day 1 every 14 days. Patients will be further randomized to additional celecoxib (Celebrex) (400 mg twice a day) or placebo.

QUASAR Group

In addition, the QUASAR (Quick and Simple and Reliable) group plans to enroll about 3,500 stage II/III colorectal cancer patients in a phase III adjuvant trial evaluating three treatment regimens:

  • Bolus 5-FU (370 mg/m²) and leucovorin (20 mg/m²) weekly for 30 weeks or the same regimen delivered on days 1 to 5 every 28 days for 24 weeks.

  • Capecitabine (1,000 mg/m² bid on days 1 to 14) plus irinotecan (250 mg/m² on day 1 every 21 days) for 12 weeks.

  • Capecitabine (1,000 mg/m² bid on days 1 to 14) plus irinotecan (250 mg/m² on day 1 every 21 days) for 24 weeks.

"Capecitabine has the potential to replace IV 5-FU in combination therapy for colorectal cancer," Dr. Kerr concluded. "It is an effective and convenient—and scientifically logical—partner for irinotecan. The planned phase III trials should give us a much clearer definition of the role of this combination both in the management of advanced colorectal cancer and in the adjuvant setting."

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content